Gail J. Roboz, MD, summarizes the sessions she presented and debates she took part in at this year's congress.

Dr Maiti discusses findings from a trial of 10-day decitabine plus venetoclax for patients with newly diagnosed, intensive chemo–ineligible, and relapsed/refractory AML.

Dr Percival provides her insight on how the treatment landscape has evolved thus far for patients with AML, and therapies that are currently in the pipeline.

Amer Zeidan, MBBS, discusses a trial exploring onvansertinib plus standard-of-care chemo in patients with AML.

Courtney DiNardo, MD, discusses the results from the VIALE-A study, which evaluated azacitidine with or without venetoclax in older patients with newly diagnosed AML.

Dr Roboz gives attendees a taste of what's to come at this year's virtual Great Debates & Updates in Hematologic Malignancies.

Courtney DiNardo, MD, MSCE, discusses the promising results from a phase 1b/2 study exploring ivosidenib in combination with venetoclax and azacitidine for IDH1-mutated AML.

Naval Daver, MD, discusses the results of a phase 2 study exploring azacitidine plus nivolumab and ipilimumab for patients with relapsed/refractory AML.